Search for content, post, videos
Advertisement

HVR Cardio closes a 11 million USD financing round

The Series B financing round of HVR Cardio was led by Finnish Innovestor Life Science Fund and Tesi.

The Finnish cardiovascular device company HVR Cardio is developing a catheter-based solution CathHELIX, which makes it possible to repair the fault without the need for demanding open-heart surgery. The solution has already been granted Breakthrough Device Designation status by the FDA (United States Food and Drug Administration).

“A fantastic example of the world-leading innovation capacity in life sciences in the Nordics”

The funding round is one of the largest rounds raised by a Finnish company in the med tech sector, states Innovestor.

Advertisement

“HVR Cardio is a fantastic example of the world-leading innovation capacity in life sciences in the Nordics, and a company that can help solve a global health burden,” says Pekka Simula, Partner of the Innovestor Life Science fund. “We are truly excited about their minimally invasive CathHELIX technology, which we expect to reach clinical translation soon and offer new hope for patients.”

In addition to the financing, the Helsinki-based HVR Cardio announces new management team members with the hiring of CEO Tom Fleming and CTO Tim Girton. Both have long histories with Boston Scientific, one of the leading global med tech players in the cardiovascular space.

Photo: iStock

Advertisement